AEON
AEON Biopharma, Inc. (AEON) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D-). The rating has held at C for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C+ (2.5) | C+ (2.6) | C- (2.1) | D- (1.1) | C+ (2.6) | C (2.2) |
| 2026-11-10 | C+ (2.5) | C+ (2.6) | C- (2.1) | D (1.3) | C+ (2.6) | C (2.2) |
| 2026-11-03 | C+ (2.5) | C+ (2.6) | C- (2.1) | D+ (1.8) | C+ (2.7) | C (2.3) |
| 2026-10-27 | C+ (2.5) | C+ (2.6) | C- (2.1) | D+ (1.6) | C+ (2.6) | C (2.3) |
| 2026-10-20 | C+ (2.5) | C+ (2.6) | C- (2.1) | D (1.4) | C+ (2.6) | C (2.2) |